Haploinsufficiency is a major underlying cause in human RP patients carrying PRPF31 mutations and the severity of RP is related to the variant expression level of remaining wild type PRPF31, thus, gene augmentation is a suitable therapeutic approach for this condition (Rivolta et al., 2006). This evidence concerns the gene PRPF31 and retinitis pigmentosa 1.